Heart failure is a major public health problem affecting 23 million people worldwide. Most of patients must be frequently monitored. Acute decompensated Heart Failure, defined as “gradual or rapid change in heart failure signs and symptoms resulting in a need for urgent therapy”, constitutes the main causes of rehospitalization in patients living with Heart Failure. The medical treatment are drugs, that requires approximately 4.5 months for patients’ conditions stabilization. The best of medical guidelines for the treatment of Heart Failure are however progressing quickly to enable them to be stabilized and kept in improving life conditions. However, it is tough to keep those patients at the best possible health levels as decompensations are often difficult to recover from and instabilities are creating many comorbidities and in pathology rapid health degradations. In order to cover this need, DYNABIO final target is a medical portable monitoring device able to ensure a continuous monitoring of the main HF biomarkers by using non-invasive biocompatible sensors. The device would allow the continuous monitoring of unstable patients without request to have frequent blood samples sent to analysis robots. It will combine the practical use of a telemedicine monitoring tool capable to copilot the patient health dynamically with the accurate measurement of main HF biomarkers from the sensors sampling in subcutaneous fluids or micro vascularized blood samples. The project will last 42 months with 3 axes of work, with the aim to provide all proof of feasibility required for the final target output of being able to create a large industrialization project from applied R&D, leveraging the project results: - Stream 1: Development to a sufficiently high TRL level (to create an industrialization plan) for the biocompatible molecularly imprinted materials targeted at the selected biomarker families; - Stream 2: Development to a sufficiently high TRL level (to create an industrialization plan) of a solution to integrate the material into a device using optical fibers for signal collection; - Stream 3: Validation and Industrialization Gate elements, with the aim to lift all the necessary elements of this feasibility study into an industrially applied project. The aim of this project is to develop the science-to-technology pre-requisites for a micro invasive device able to perform continuous monitoring. If this project is successful, the subsequent goal will be to raise the required resources (up to 20/30 M€) from private and collaborative R&D to finance industrialization. For that, the project is based on a largely used biomarker family and a sensor design with a strong IP creation potential. In fact, at the end of the project, BioSerenity, as the unique economic actor of the project, will have established a business case for the technological transfer of project innovations. In particular, public and private partners will have been identified for the industrialization of the product, as well as potential funders, in order to demonstrate its technical and economic viability, based on the exploitation of intellectual property resulting from the project. The DYNABIO project is supported by three organizations: - BioSerenity, a fast-growing innovative company which combines high tech engineering, medical development and big data analytics; - The Université de Technologie de Compiègne, a public research university located in Compiègne; - The Institut de Science des Matériaux de Mulhouse, a CNRS-University de Haute-Alsace mixed research unit located in Mulhouse. The total budget for the project is €1,135,644, with a requested funding of €575,598. The remaining part of the budget will be self-financed by BioSerenity.